P. Rawla, T. Sunkara, V. Gaduputi, Epidemiology of pancreatic Cancer: global trends, etiology and risk factors. World J. Oncol. 10(1), 10–27 (2019). https://doi.org/10.14740/wjon1166

Article  PubMed  PubMed Central  Google Scholar 

H. Sung, J. Ferlay, R.L. Siegel et al., Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71(3), 209–249 (2021). https://doi.org/10.3322/caac.21660

Article  CAS  PubMed  Google Scholar 

J.D. Mizrahi, R. Surana, J.W. Valle et al., Pancreatic cancer. Lancet. 395(10242), 2008–2020 (2020). https://doi.org/10.1016/s0140-6736(20)30974-0

Article  CAS  PubMed  Google Scholar 

N.A. Ullman, P.R. Burchard, R.F. Dunne et al., Immunologic strategies in pancreatic Cancer: making Cold tumors Hot. J. Clin. Oncol. 40(24), 2789–2805 (2022). https://doi.org/10.1200/jco.21.02616

Article  CAS  PubMed  PubMed Central  Google Scholar 

A.A. Connor, S. Gallinger, Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data. Nat Rev Cancer. 22(3): 131– 42 (2022). https://doi.org/10.1038/s41568-021-00418-1

C.J. Halbrook, C.A. Lyssiotis, M. Pasca di Magliano et al., Pancreatic cancer: advances and challenges. Cell. 186(8), 1729–1754 (2023). https://doi.org/10.1016/j.cell.2023.02.014

Article  CAS  PubMed  PubMed Central  Google Scholar 

L.J. Padrón, D.M. Maurer, M.H. O’hara et al., Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial. Nat. Med. 28(6), 1167–1177 (2022). https://doi.org/10.1038/s41591-022-01829-9

Article  CAS  PubMed  PubMed Central  Google Scholar 

M.M. Wattenberg, D. Asch, S. Yu et al., Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation. Br. J. Cancer. 122(3), 333–339 (2020). https://doi.org/10.1038/s41416-019-0582-7

Article  CAS  PubMed  Google Scholar 

Z.A. Wainberg, H.S. Hochster, E.J. Kim et al., Open-label, phase I study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer. Clin. Cancer Res. 26(18), 4814–4822 (2020). https://doi.org/10.1158/1078-0432.Ccr-20-0099

Article  CAS  PubMed  Google Scholar 

S.M. Liudahl, C.B. Betts, S. Sivagnanam et al., Leukocyte heterogeneity in pancreatic ductal adenocarcinoma: phenotypic and spatial features Associated with clinical outcome. Cancer Discov. 11(8), 2014–2031 (2021). https://doi.org/10.1158/2159-8290.Cd-20-0841

Article  PubMed  PubMed Central  Google Scholar 

B. Uzunparmak, I.H. Sahin, Pancreatic cancer microenvironment: a current dilemma. Clin. Transl Med. 8(1), 2 (2019). https://doi.org/10.1186/s40169-019-0221-1

Article  PubMed  PubMed Central  Google Scholar 

J. Watt, H.M. Kocher, The desmoplastic stroma of pancreatic cancer is a barrier to immune cell infiltration. Oncoimmunology. 2(12), e26788 (2013). https://doi.org/10.4161/onci.26788

Article  PubMed  PubMed Central  Google Scholar 

S. Zhang, W. Fang, S. Zhou et al., Single cell transcriptomic analyses implicate an immunosuppressive tumor microenvironment in pancreatic cancer liver metastasis. Nat. Commun. 14(1), 5123 (2023). https://doi.org/10.1038/s41467-023-40727-7

Article  CAS  PubMed  PubMed Central  Google Scholar 

T. Krausgruber, N. Fortelny, V. Fife-Gernedl et al., Structural cells are key regulators of organ-specific immune responses. Nature. 583(7815), 296–302 (2020). https://doi.org/10.1038/s41586-020-2424-4

Article  CAS  PubMed  PubMed Central  Google Scholar 

C. Neuzillet, A. Tijeras-Raballand, C. Ragulan et al., Inter- and intra-tumoural heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma. J. Pathol. 248(1), 51–65 (2019). https://doi.org/10.1002/path.5224

Article  CAS  PubMed  PubMed Central  Google Scholar 

H. Huang, Z. Wang, Y. Zhang et al., Mesothelial cell-derived antigen-presenting cancer-associated fibroblasts induce expansion of regulatory T cells in pancreatic cancer. Cancer Cell. 40(6): 656– 73.e7 (2022). https://doi.org/10.1016/j.ccell.2022.04.011

A. Lo, C.P. Li, E.L. Buza et al., Fibroblast activation protein augments progression and metastasis of pancreatic ductal adenocarcinoma. JCI Insight. 2(19) (2017). https://doi.org/10.1172/jci.insight.92232

X. Liu, J. Xu, B. Zhang et al., The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications. Mol. Cancer. 18(1), 184 (2019). https://doi.org/10.1186/s12943-019-1117-9

Article  PubMed  PubMed Central  Google Scholar 

K. Chen, Q. Wang, M. Li et al., Single-cell RNA-seq reveals dynamic change in tumor microenvironment during pancreatic ductal adenocarcinoma malignant progression. EBioMedicine. 66, 103315 (2021). https://doi.org/10.1016/j.ebiom.2021.103315

Article  CAS  PubMed  PubMed Central  Google Scholar 

J.L. Carstens, P. Correa de Sampaio, D. Yang et al., Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer. Nat. Commun. 8, 15095 (2017). https://doi.org/10.1038/ncomms15095

Article  PubMed  PubMed Central  Google Scholar 

B.T. Grünwald, A. Devisme, G. Andrieux et al., Spatially confined sub-tumor microenvironments in pancreatic cancer. Cell. 184(22), 5577–92e18 (2021). https://doi.org/10.1016/j.cell.2021.09.022

Article  CAS  PubMed  Google Scholar 

B.A. Helmink, S.M. Reddy, J. Gao et al., B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 577(7791): 549– 55 (2020). https://doi.org/10.1038/s41586-019-1922-8

Z.R. Qian, D.A. Rubinson, J.A. Nowak et al., Association of alterations in main driver genes with outcomes of patients with resected pancreatic ductal adenocarcinoma. JAMA Oncol. 4(3), e173420 (2018). https://doi.org/10.1001/jamaoncol.2017.3420

Article  PubMed  Google Scholar 

M. Peng, Y. Ying, Z. Zhang et al., Reshaping the pancreatic Cancer microenvironment at different stages with chemotherapy. Cancers (Basel). 15(9) (2023). https://doi.org/10.3390/cancers15092448

C. Mota Reyes, S. Teller, A. Muckenhuber et al., Neoadjuvant therapy remodels the pancreatic Cancer Microenvironment via Depletion of Protumorigenic Immune cells. Clin. Cancer Res. 26(1), 220–231 (2020). https://doi.org/10.1158/1078-0432.Ccr-19-1864

Article  PubMed  Google Scholar 

A. Dias Costa, S.A. Väyrynen, A. Chawla et al., Neoadjuvant Chemotherapy is Associated with altered Immune Cell Infiltration and an anti-tumorigenic microenvironment in Resected Pancreatic Cancer. Clin. Cancer Res. 28(23), 5167–5179 (2022). https://doi.org/10.1158/1078-0432.Ccr-22-1125

Article  CAS  PubMed  Google Scholar 

M.H. Andersen, Novel immune modulatory vaccines targeting TGFβ. Cell. Mol. Immunol. 20(5), 551–553 (2023). https://doi.org/10.1038/s41423-023-01000-5

Article  CAS  PubMed  PubMed Central  Google Scholar 

S. Li, H.X. Xu, C.T. Wu et al., Angiogenesis in pancreatic cancer: current research status and clinical implications. Angiogenesis. 22(1), 15–36 (2019). https://doi.org/10.1007/s10456-018-9645-2

Article  PubMed  Google Scholar 

de K.E. Visser, J.A. Joyce, The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell. 41(3), 374–403 (2023). https://doi.org/10.1016/j.ccell.2023.02.016

Article  CAS  PubMed  Google Scholar 

P.J. Campbell, S. Yachida, L.J. Mudie et al., The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature. 467(7319), 1109–1113 (2010). https://doi.org/10.1038/nature09460

Article  CAS  PubMed  PubMed Central  Google Scholar 

S. Yachida, S. Jones, I. Bozic et al., Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 467(7319), 1114–1117 (2010). https://doi.org/10.1038/nature09515

Article  CAS